Open access

Heterogeneity in plasma p‐tau217 response and its association with cognitive trajectories under lecanemab treatment

Sung-Hoon Kang Yu Jeong Park Seung-Yun Lee Jimin Kang Seongin Lee Eun Seong Lee Hye Na Jung I. Ryoo Hyundoo Hwang Kwangho Choi Jae Seon Eo Sang-Il Suh Kyungmi Oh Seong-Beom Koh

Jul 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 28 references

Medicine

Abstract

Plasma phosphorylated tau 217 (p‐tau217) is a promising biomarker for monitoring treatment response in Alzheimer's disease (AD), but its longitudinal dynamics and clinical relevance remain unclear.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Aug 2026

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.

Guo-Yu Lan, Wang Liao, Mingxing Jiang et al. · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment

The role of complement in Alzheimer's disease (AD) remains unclear, particularly regarding tau pathology and memory decline.

Zhi-Nan Ye, Qi-Han Zhang, Bo Zhang et al. · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Evaluating the 8‐Year Association Between Cognition and Beta Amyloid in the Dallas Lifespan Brain Study Cohort

Mounting evidence suggests beta amyloid (Aβ) is not the sole initiating driver of cognitive decline in Alzheimer's disease (AD). This study explores whether there is an association between cognitive decline over eight years and Aβ.

J. David, Isabella Torres, Evan Smith et al. · Brain and Behavior · 0 citations

Open access Sep 2026

Brain‐derived plasma p‐tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change

Brain‐derived p‐tau217 may reduce these off‐target effects of Alzheimer's disease pathology, but its performance against neuropathology has not been evaluated.

Marisa N. Denkinger, W. Brum, A. Leuzy et al. · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Hippocampal Volume Mediates the Association Between Serum Ferritin and Cognition in Non‐Dialysis End‐Stage Renal Disease Patients

Quantitatively assess the characteristics of brain volume in end‐stage renal disease (ESRD) individuals through high‐resolution structural MRI, analyze the relationship between these features and cognitive impairment, as well as explore associated risk factors.

Jing-Jing Si, Ming-Hua Zhu, Ming-Zhe Dai · Brain and Behavior · 0 citations

Open access Sep 2026

Protein Biomarkers in Risk and Prognosis of Amyotrophic Lateral Sclerosis

Plasma and cerebrospinal fluid (CSF) protein biomarkers in amyotrophic lateral sclerosis (ALS) may provide insight into disease mechanisms and yield clinically useful biomarkers.

Lu Pan, C. Hou, Christina Seitz et al. · European Journal of Neurolog... · 0 citations